Prostate Cancer
Complications and treatment for metastatic prostate cancer are reviewed
Published in Clinical Oncology Week, September 29th, 2003
"Despite highly successful treatments for localized prostate cancer, approximately 35% to 40% of men will eventually experience a detectable rise in serum prostate specific antigen," researchers in the United States report.
"A portion of these men will go on to experience clinically expressed extracapsular disease, with as many as two-thirds having evidence of bone involvement. Diagnosis of skeletal involvement involves serum markers of disease progression and radiological evaluation," wrote C.T. McMurtry and colleagues, McGuire Veterans Affairs Medical Center, Geriatric &...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Imaging
18F-FLT more accurate than 18F-FDG for differentiating unclear lung lesions - Melanoma
CD80+ B-cell levels may predict melanoma outcome - Bladder Tumors
MRI can perform dynamic bladder imaging without radiation exposure - Cancer Therapy
Drug developed for rare disease may help millions more as cancer treatment - Cervical Lesions
Researchers compare cytology and colposcopy for diagnosing cervical lesions - Lung Cancer
Weekly low-dose paclitaxel, cisplatin safe for advanced NSCLC - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
